MedPath

Efficacy of Selegiline in Negative Symptoms of Schizophrenia

Early Phase 1
Completed
Conditions
Schizophrenia
Registration Number
NCT00456976
Lead Sponsor
Tabriz University
Brief Summary

Antipsychotic drugs are effective in treating the positive symptoms of schizophrenia; however their efficacy in treating negative symptoms is limited. This study wants to evaluate efficacy of selegiline augmentation of antipsychotic medication to treat negative symptoms in inpatients with chronic schizophrenia. With randomized clinical trial two groups of patients will select to receive selegiline or placebo.

Primary end point is decreasing in negative symptoms in case group. Inclusion criteria : 1- Patients with moderate to severe negative symptoms 2- Patients with at least one year antipsychotic drug therapy, at the current dose \>= 1 month. 3- No other psychotropic drugs during past month. Exclusion criteria: 1- Severe major depressive disorder, substance abuse, severe positive symptoms of schizophrenia, Treatment of MDD with antidepressant drugs during past month.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Patients with moderate to severe negative symptoms
  • Patients with at least one year antipsychotic drug therapy, at the current dose >= 1 month.
  • No other psychotropic drugs during past month
Exclusion Criteria
  • Severe major depressive disorder
  • Substance abuse
  • Severe positive symptoms of schizophrenia
  • Treatment of MDD with antidepressant drugs during past month.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
decreasing in negative symptoms in case group
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Razi university hospital

🇮🇷

Tabriz, East Azarbaijan, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath